Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Entrada Therapeutics Q2 EPS $(1.04) Misses $(0.85) Estimate, Sales $1.950M Miss $9.651M Estimate

Author: Benzinga Newsdesk | August 06, 2025 06:34am
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.85) by 22.64 percent. This is a 167.1 percent decrease over earnings of $1.55 per share from the same period last year. The company reported quarterly sales of $1.950 million which missed the analyst consensus estimate of $9.651 million by 79.80 percent. This is a 97.94 percent decrease over sales of $94.694 million the same period last year.

Posted In: TRDA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist